Navigation Links
SuperGen in Medical News

SuperGen Reports 2008 Fourth Quarter and Year-End Financial Results

... DUBLIN, Calif., March 2 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company ..., representing approximately 1.5 million shares of supergen common stock. December 2008: The...employees. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2008 Fourth Quarter and Fiscal Year-End Financial Results March 2, 2009

...eplay and conference call replay will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at BIO CEO & Investor Conference on February 10, 2009

...t www.supergen.com . The webcast will be archived for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a pharmaceutical company dedicated to the discovery and development of novel cancer therapies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Present at the Collins Stewart Growth Conference on July 9, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

QED International Associates Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...aq: OREX ) Repros Therapeutics Inc. (Nasdaq: RPRX ) Sangamo BioSciences Inc. (Nasdaq: SGMO ) Sirtris Pharmaceuticals, Inc. (Nasdaq: SIRT ) supergen Inc. (Nasdaq: SUPG ) Transition Therapeutics Inc. (Nasdaq: TTHI ) XOMA Ltd. (Nasdaq: XOMA ) Neuroscience Index (HHN) Drop Neurochem Inc. (...

Data Show SuperGen's Multi-Targeted Tyrosine Kinase Inhibitor Demonstrates Pre-clinical Activity in Glioblastoma Multiforme

... DUBLIN, Calif., Oct. 31 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... be a key player in this resistance. Scientists at supergen found that MP470 inhibits these kinases and data p...ignificant unmet clinical need in oncology. About supergen Based in Dublin, Calif.,...

SuperGen Reports 2007 Third Quarter Financial Results

... DUBLIN, Calif., Oct. 29 /PRNewswire-FirstCall/ -- supergen Inc., (Nasdaq: SUPG ), a pharmaceutical company d...itioned to David S. Smith, Ph.D., who joined supergen in March 2007 as Vice President, Regulatory and ...Consumer Healthcare. Conference Call Information supergen will host a conference call to discuss the results...

SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007

... DUBLIN, Calif., Oct. 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ference call will be available for 90 days. About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR-NCI-EORTC International Conference

... DUBLIN, Calif., Oct. 17 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... malignancies About supergen Based in Dublin, Calif., SuperGen, Inc. is a phar...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
SuperGen in Medical Technology

SuperGen's PIM Kinase Inhibitor, SGI-1776, Effective in Pre-Clinical Models of Acute Lymphoblastic Leukemia

... DUBLIN, Calif., Dec. 8 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company d...f Pennsylvania support this hypothesis." supergen recently received clearance for a phase I trial wi...ell as several types of leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is a ...

SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes

... DUBLIN, Calif., July 1 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG), a pharmaceutical company dedi...n was developed through a pivotal Phase 3 study by supergen and partnered to MGI PHARMA, INC. (acquired by Eis...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's JAK2 Inhibitor, SGI-1252, Inhibits in Vivo Tumor Cell Proliferation

... DUBLIN, Calif., June 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...ner, Manager of Discovery Biology, highlighted how supergen scientists used the company's CLIMB(TM) technology...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's PIM Kinase Inhibitor, SGI-1776, Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., June 13 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Identifies Lead PIM Kinase Inhibitor, SGI-1776, That Causes Tumor Regression in AML Xenograft Models

... DUBLIN, Calif., April 16 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

Data Show SuperGen's MP-470 is Safe in Humans

... DUBLIN, Calif., April 15 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen's DNA Methyltransferase Inhibitor, S-110, Improves In Vivo Efficacy Profile of Decitabine

...DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de....com . About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen's MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

...g erlotinib resistance DUBLIN, Calif., April 14 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting

... DUBLIN, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery,...ercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase...

SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor

...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...mation, future events or otherwise. Contacts: supergen Timothy L. Enns S.V.P., Corporate Communications...evelopment (925) 560-0100 tenns@supergen.com supergen Mary M. Vegh Manager, Investor Relations (925) ...
SuperGen in Biological Technology

Dr. Audrey F. Jakubowski of SuperGen Retires as Chief Regulatory and Quality Officer

Dr. David S. Smith to Head Regulatory and Quality Affairs DUBLIN, Calif., Aug. 17 /PRNewswire-FirstCall/ -- SuperGen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malign...

SuperGen Receives Clearance to Begin Clinical Trials With SGI-1776, a PIM Inhibitor

..., representing approximately 1.5 million shares of supergen common stock. supergen will initiate a Phase I clinical trial to evaluate...as several types of human leukemias. About supergen Based in Dublin, Calif., SuperGen, Inc. is...

SuperGen Reports 2008 Third Quarter Financial Results

...act 571: Modulation of JAK2 signaling pathways in vitro and in vivo by SGI-1252, a small molecule JAK2 inhibitor. Conference Call Information supergen will host a conference call to discuss the 2008 third quarter financial results today at 1:30 p.m. PT / 4:30 p.m. ET. The webcast will be accessible v...

SuperGen to Announce 2008 Third Quarter Financial Results November 4, 2008

... DUBLIN, Calif., Oct. 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company dedicated to the discovery ... will be available for 90 days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the discovery and development...

SuperGen's MP-470 Demonstrates Clinical Tumor Regression When Combined with Standard of Care Chemotherapy

... drug designation for GBM, an often fatal form of brain cancer, can entitle supergen to seven years of market exclusivity. SuperGen's lead product candidate has...e spectrum of cancers, including non-small cell lung cancer. Furthermore, supergen presented four additional posters at the Symposium that reviewed clinical a...

SuperGen Reports 2008 Second Quarter Financial Results

...nager of Discovery Biology, highlighted how supergen scientists used the Company's CLIMB technology to ... scientific forum. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Present at FBR Capital Markets 12th Annual Spring Investor Conference on May 29, 2008

...armaceutical company dedicated to the discovery, rapid development and commercialization of therapies for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer products focused on kinase and cell signaling inhibitors and DNA methyltransferase inhibitors. For mo...

SuperGen Reports 2008 First Quarter Financial Results

...DUBLIN, Calif., April 28 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ) today reported financial res...red to decitabine. Conference Call Information supergen will host a conference call to discuss the results...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Webcast 3rd Annual Analyst Day on April 29, 2008

...DUBLIN, Calif., April 22 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de...event. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...

SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008

...DUBLIN, Calif., April 21 /PRNewswire-FirstCall/ -- supergen Inc. (Nasdaq: SUPG ), a pharmaceutical company de... days. About SuperGen Based in Dublin, Calif., supergen Inc. is a pharmaceutical company dedicated to the ...s for solid tumors and hematological malignancies. supergen is developing a number of therapeutic anticancer p...
Other Tags
(Date:9/23/2014)... health care in the early 20th century, helping ... But bacteria are also constantly outsmarting science, and ... more frequently. This week,s Speaking of Chemistry focuses ... discusses the prospects for new drugs. The episode ... your pills if you feel better? Check it ...
(Date:9/23/2014)... -- Contrary to what is often assumed about single ... study from The Kinsey Institute has found that single ... sexually active as often as singles without children -- ... , The study, "Dating and Sexual Behavior Among Single ... published online in the Journal of Sex Research ...
(Date:9/23/2014)... On September 23, 2014, My Positive Perspective ... episode. Simmons is the founder of Traveler of Charleston magazine ... like to know. At the start of the interview, Deierlein ... this magazine?” Simmons replied by saying, “I had worked for ... I quit that and decided to start my own magazine ...
(Date:9/23/2014)... On September 20- 21, 2014, people from all over ... Trivedi Retreat ‘Consciousness is Power’, online as well as ... from Mahendra Trivedi and Trivedi Masters™ Dahryn Trivedi and ... In-person, group and live Energy Transmissions and also listened ... Master™ Alice Branton, where, they described about the importance ...
(Date:9/23/2014)... HealthDay Reporter MONDAY, Sept. 22, 2014 (HealthDay ... five heart attacks in men, a new study suggests. ... attacks over an average of 11 years if they drank moderately, ... weight fronts, the study found. Only about 1 percent ... But they were 86 percent less likely to have heart attacks ...
Breaking Medicine News(10 mins):Health News:Kinsey study of single parents' dating, sexual activity contradicts assumptions 2Health News:My Positive Perspective Airs Episode With the Founder of Traveler of Charleston Magazine 2Health News:The Trivedi Retreat ‘Consciousness is Power’ was Huge Success 2Health News:The Trivedi Retreat ‘Consciousness is Power’ was Huge Success 3Health News:Study: Healthy Lifestyle Behaviors May Prevent 80 Percent of Heart Attacks 2Health News:Study: Healthy Lifestyle Behaviors May Prevent 80 Percent of Heart Attacks 3
(Date:9/22/2014)... the University of Chicago have shown that after a ... a handful of pathogenic microbe species remain behind in ... discovered that some can become deadly when provoked by ... , The findings, published in mBio , the ... may lead to better monitoring and treatment of ICU ...
(Date:9/22/2014)... Yale University researchers are studying a potential new treatment ... disease in which scars develop in the lungs and ... mimic, miR-29, which is delivered to lung tissue intravenously. ... it reversed fibrosis after several days. , The ... EMBO Molecular Medicine . , "The mimic, when injected ...
(Date:9/22/2014)... Rochelle, NY, September 22, 2014Cassava, also known as tapioca, ... yields in areas of Africa, Asia, and Latin America ... the availability of novel enzymes and processes designed to ... be used to produce sweeteners such as glucose, fructose, ... to corn, as described in a Review article in ...
Breaking Biology News(10 mins):Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 2Critically ill ICU patients lose almost all of their gut microbesand the ones left aren't good 3Reversing the effects of pulmonary fibrosis 2
Other Contents